CIBIS II: Cardiac Insufficiency Bisoprolol Study II - PowerPoint PPT Presentation

Loading...

PPT – CIBIS II: Cardiac Insufficiency Bisoprolol Study II PowerPoint presentation | free to view - id: 263c1c-MjAxY



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

CIBIS II: Cardiac Insufficiency Bisoprolol Study II

Description:

To determine whether bisoprolol, a 1-selective adrenoreceptor blocker, reduces ... receiving standard therapy (diuretic plus ACE inhibitor/other vasodilator) ... – PowerPoint PPT presentation

Number of Views:1073
Avg rating:3.0/5.0
Slides: 8
Provided by: inci2
Category:

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: CIBIS II: Cardiac Insufficiency Bisoprolol Study II


1
CIBIS II Cardiac Insufficiency Bisoprolol Study
II
  • Purpose
  • To determine whether bisoprolol, a ß1-selective
    adrenoreceptor blocker, reduces all-cause
    mortality in chronic heart failure
  • Reference
  • CIBIS-II Investigators and Committees. The
    Cardiac Insufficiency Bisoprolol Study II
    (CIBIS-II) a randomised trial. Lancet
    1999353913.

2
CIBIS II Cardiac Insufficiency Bisoprolol
Study II - TRIAL DESIGN -
  • Design
  • Multicenter, multinational, randomized,
    double-blind, placebo-controlled
  • Patients
  • 2647 patients, aged 1880 years, with left
    ventricular ejection fraction lt35 and NYHA class
    III or IV heart failure, receiving standard
    therapy (diuretic plus ACE inhibitor/other
    vasodilator)
  • Follow up and primary end point
  • Mean 1.3 years follow up. Primary endpoint
    all-cause mortality
  • Treatment
  • Placebo or bisoprolol 1.25 mg daily, increased
    stepwise over several weeks as tolerated to
    target dose 10 mg daily

3
CIBIS II Cardiac Insufficiency Bisoprolol Study
II- RESULTS -
  • Study halted early because all-cause mortality
    significantly less in bisoprolol group than
    placebo group
  • Also significant reduction in
  • Sudden deaths
  • All cardiovascular deaths
  • All-cause hospitalization, as well as
    hospitalization due to worsening heart failure
  • Treatment effects independent of severity or
    cause of heart failure
  • Drug well tolerated as defined by permanent early
    treatment withdrawals (15 in both groups, P0.98)

4
CIBIS II Cardiac Insufficiency Bisoprolol Study
II- RESULTS continued-

All-cause mortality
Survival
1.0
0.8
0.6
Placebo
Plt0.0001
Bisoprolol
0
200
800
600
400
Days after inclusion
CIBIS-II Investigators and Committees.
Lancet
1999
353
9

13.
5
CIBIS II Cardiac Insufficiency Bisoprolol Study
II- RESULTS continued-

Primary and secondary outcomes
Placebo
Bisoprolol
Hazard ratio
P
(n1320)
(n1327)
(95 CI)
()
()
Primary endpoint
All-cause mortality
17
12
0.66 (0.54

0.81)
lt0.0001




Secondary endpoints
All-cause hospital admission
39
33
0.80 (0.71

0.91)
0.0006
All cardiovascular deaths
12
9
0.71 (0.56

0.90)
0.0049
Combined endpoint
35
29
0.79 (0.69

0.90)
0.0004




Exploratory analyses
Sudden death
6
4
0.56 (0.39

0.80)
0.0011
Hospital admission for
18
12
0.64 (0.53

0.79)
0.0001
worsening heart failure
CIBIS-II Investigators and Committees.
Lancet
1999
353
9

13.
6
CIBIS II Cardiac Insufficiency Bisoprolol Study
II- RESULTS continued-

Effect of bisoprolol on subgroups
Baseline etiology/
Bisoprolol
Placebo
functional class
(n/total)
(n/total)
Ischemia
75/662
121/654
Primary dilated
13/160
15/157
cardiomyopathy


Undefined
68/505
92/509
NYHA III
116/1106
173/1096
NYHA IV
40/221
55/224
Total
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
Relative risk (and 95 CI)
CIBIS-II Investigators and Committees.
Lancet
1999
353
9

13.
7
CIBIS II Cardiac Insufficiency Bisoprolol Study
II- SUMMARY -
  • In patients with class III or IV heart failure,
    bisoprolol in addition to standard therapy
    reduced
  • All-cause mortality
  • Sudden death and cardiovascular death
  • All-cause hospitalization and hospitalization due
    to worsening heart failure
About PowerShow.com